Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva M M Strijbis

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Multiple Sclerosis and Related Disorders|June 25, 2025
Verona validation of the DAAE score, a tool for estimating risk of clinical disease progression in people with multiple sclerosisTom A Fuchs, Stefano Ziccardi, Julia R Jelgerhuis, et al.
Annals of Clinical and Translational Neurology|July 8, 2023
The role of diet in multiple sclerosis onset and course: results from a nationwide retrospective birth-year cohortFloor C Loonstra, Lodewijk R J de Ruiter, Menno M Schoonheim, et al.
Investigative Ophthalmology & Visual Science|January 24, 2012
The physiological variation of the retinal nerve fiber layer thickness and macular volume in humans as assessed by spectral domain-optical coherence tomographyLisanne J Balk, Judith M Sonder, Eva M M Strijbis, et al.
International Journal of Molecular Sciences|December 10, 2021
Myelin Quantification in White Matter Pathology of Progressive Multiple Sclerosis Post-Mortem Brain Samples: A New Approach for Quantifying RemyelinationMarije J D Huitema, Eva M M Strijbis, Antonio Luchicchi, et al.
Neurology|February 17, 2025
Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple SclerosisEva M M Strijbis, Jop Mostert, Jacynthe Comtois, et al.
Neurology|September 13, 2024
Association of Polygenic Risk Score With Lifetime Risk of Developing Multiple Sclerosis in a Population-Based Birth-Year CohortFloor C Loonstra, Daniel Álvarez Sirvent, Niccoló Tesi, et al.
Neurology|May 12, 2025
Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple SclerosisEva A Krijnen, Julia Jelgerhuis, Maureen Van Dam, et al.
Multiple Sclerosis and Related Disorders|February 11, 2025
Which type of PROMs to use in MS routine clinical care: The validity of PROMIS CAT questionnairesHeleen Beckerman, Isaline C J M Eijssen, Roos Walraven, et al.
Journal of the Neurological Sciences|November 14, 2025
Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumabLiza M Y Gelissen, Laura Hogenboom, Alyssa A Toorop, et al.
Journal of the Neurological Sciences|May 1, 2026
No interferon-beta antibodies in natalizumab-treated multiple sclerosis patients with progressive multifocal leukoencephalopathyLiza M Y Gelissen, Martijn T Wijburg, Eva M M Strijbis, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Multiple Sclerosis and Related Disorders|June 25, 2025
Verona validation of the DAAE score, a tool for estimating risk of clinical disease progression in people with multiple sclerosisTom A Fuchs, Stefano Ziccardi, Julia R Jelgerhuis, et al.
Annals of Clinical and Translational Neurology|July 8, 2023
The role of diet in multiple sclerosis onset and course: results from a nationwide retrospective birth-year cohortFloor C Loonstra, Lodewijk R J de Ruiter, Menno M Schoonheim, et al.
Investigative Ophthalmology & Visual Science|January 24, 2012
The physiological variation of the retinal nerve fiber layer thickness and macular volume in humans as assessed by spectral domain-optical coherence tomographyLisanne J Balk, Judith M Sonder, Eva M M Strijbis, et al.
International Journal of Molecular Sciences|December 10, 2021
Myelin Quantification in White Matter Pathology of Progressive Multiple Sclerosis Post-Mortem Brain Samples: A New Approach for Quantifying RemyelinationMarije J D Huitema, Eva M M Strijbis, Antonio Luchicchi, et al.
Neurology|February 17, 2025
Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple SclerosisEva M M Strijbis, Jop Mostert, Jacynthe Comtois, et al.
Neurology|September 13, 2024
Association of Polygenic Risk Score With Lifetime Risk of Developing Multiple Sclerosis in a Population-Based Birth-Year CohortFloor C Loonstra, Daniel Álvarez Sirvent, Niccoló Tesi, et al.
Neurology|May 12, 2025
Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple SclerosisEva A Krijnen, Julia Jelgerhuis, Maureen Van Dam, et al.
Multiple Sclerosis and Related Disorders|February 11, 2025
Which type of PROMs to use in MS routine clinical care: The validity of PROMIS CAT questionnairesHeleen Beckerman, Isaline C J M Eijssen, Roos Walraven, et al.
Journal of the Neurological Sciences|November 14, 2025
Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumabLiza M Y Gelissen, Laura Hogenboom, Alyssa A Toorop, et al.
Journal of the Neurological Sciences|May 1, 2026
No interferon-beta antibodies in natalizumab-treated multiple sclerosis patients with progressive multifocal leukoencephalopathyLiza M Y Gelissen, Martijn T Wijburg, Eva M M Strijbis, et al.
Pageof 6